A case for judicious use of risperidone and olanzapine in behavioral and psychological symptoms of dementia (BPSD): Commentary

International Psychogeriatrics

Volumn 17, Issue 1, 2005, Pages 22-29

  McKeith, Ian ^a  

^a NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

BEHAVIOR DISORDER; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; DEMENTIA; DRUG EFFICACY; EVIDENCE BASED MEDICINE; FALLING; GLUCOSE BLOOD LEVEL; HUMAN; NOTE; PARKINSONISM; PRACTICE GUIDELINE; PRESCRIPTION; RISK BENEFIT ANALYSIS; SIDE EFFECT; STROKE; SYMPTOMATOLOGY; TRANSIENT ISCHEMIC ATTACK; WEIGHT GAIN;

EID: 17844386561     PISSN: 10416102     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1041610205241029     Document Type: Note

References (83)

1. Ballard, C., Grace, J., McKeith, I. and Holmes, C. (1998). Neuroleptic sensitivity in dementia with Lewy bodies and Alzheimer's disease. Lancet, 351, 1032-1033.
2. Ballard, C. et al. (2001). Quality of life for people with dementia living in nursing home and residential care. International Psychogeriatrics, 13, 93-106.
3. Ballard, C., O'Brien, J., Swann, A. and James, I. (2002). Treating Behavioral and Psychological Symptoms of Dementia. Oxford University Press, Oxford, U.K.
4. Ballard, C. et al. (2002). Can psychiatric liaison reduce neuroleptic use and reduce health service utilization for dementia patients residing in care facilities. International Journal of Geriatric Psychiatry, 17, 140-145.
5. Ballard, C. G. and O'Brien, J. (1999). Pharmacological treatment of behavioral and psychological signs in Alzheimer's disease: how good is the evidence for current pharmacological treatments? British Medical Journal, 319, 138-139.
6. Ballard, C. G., Shaw, F., Lowery, K., McKeith, I. and Kenny, R. (1999). The prevalence, assessment and associations of falls in dementia with Lewy bodies and Alzheimer's disease. Dementia and Geriatric Cognitive Disorders, 10, 97-103.
7. Ballard, C. G. et al. (2004). Three-month randomized placebo-controlled neuroleptic discontinuation study in 100 people with dementia: the Neuropsychiatric Inventory median cut-off is a predictor of clinical outcome. Journal of Clinical Psychiatry, 65, 114-119.
8. Ballard, C. G. (2004). (Abstract) Dementia with Lewy bodies: update, definition and clinical studies. Proceedings of the 9th international conference on Alzheimer's disease, 53-04-04.
9. Ballard, C. et al. (2005). Is the atypical neuroleptic quetiapine or the cholinesterase inhibitor rivastigmine associated with altered cognitive decline in Alzheimer's disease? BMJ (in press).
10. Herman, I., Merson, A., Rachov-Pavlov, J., Allan, E., Davidson, M. and Losoncyz, M. F. (1996). Risperidone in elderly schizophrenic patients. The American Journal of Geriatric Psychiatry, 4, 173-179.
11. Bridges-Parlet, S., Knopman, D. and Steffes, S. (1997). Withdrawal of neuroleptic medications from institutionalized dementia patients: results of a double-blind, baseline-treatment-controlled pilot study. Journal of Geriatric Psychiatry and Neurology, 10, 119-126.
12. Brodaty, H. et al. (2003). A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. Journal of Clinical Psychiatry, 64, 134-143.
13. Burns, A., Byrne, J., Ballard, C. and Holmes, C. (2002). Sensory stimulation in dementia. British Medical Journal, 325, 1312-1313.
14. Burns, A., Jacoby, R. and Levy, R. (1990a). Psychiatric phenomena in Alzheimer's disease. I. Disorders of thought content. British Journal of Psychiatry, 15, 72-76.
15. Burns, A., Jacoby, R. and Levy, R. (1990b). Psychiatric phenomena in Alzheimer's disease. II: Disorders of perception. British Journal of Psychiatry, 157, 76-81.
16. Burns, A., Jacoby, R. and Levy, R. (1990c). Psychiatric phenomena in Alzheimer's disease. III. Disorders of mood. British Journal of Psychiatry, 157, 81-86.
17. Burns, A., Jacoby, R. and Levy, R. (199Od). Psychiatric phenomena in Alzheimer's disease IV. Disorders of behaviour. British Journal of Psychiatry, 157, 86-94.
18. Camp, C. J., Cohen-Mansfield, J. and Capezuti, E. A. (2002). Use of non-pharmacological interventions among nursing home residents with dementia. Mental Health Services in Nursing Homes, 53, 1397-1401.
19. Chan, W. C., Lam, L. C., Choy, C. N., Leung, V. P., Li, S. and Chiu, H. F. (2001). A double-blind randomised comparison of risperidone and haloperidol in the treatment of behavioural and psychological symptoms in Chinese dementia patients. International Journal of Geriatric Psychiatry, 16, 1156-1162.
20. Chen, C. P. et al. (1996). Presynaptic serotonergic markers in community-acquired cases of Alzheimer's disease: correlations with depression and neuroleptic medication. Journal of Neurochemistry, 66, 1592-1598.
21. Chlan-Fourney, J., Ashe, P., Nylen, K., Juorio, A. V. and Li, X. M. (2002). Differential regulation of hippocampal BDNF mRNA by typical and atypical antipsychotic administration. Brain Research, 954, 11-20.
22. Clark, W. S., Street, J. S., Feldman, P. D. and Breier, A. (2001). The effects of olanzapine in reducing the emergence of psychosis among nursing home patients with Alzheimer's disease. Journal of Clinical Psychiatry, 62, 34-40.
23. Coffey, E. T., Akerman, K. E. and Courtney, M. J. (1997). Brain-derived neurotrophic factor induces a rapid upregulation of synaptophysin and tau proteins via the neurotrophin receptor TrkB in rat cerebellar granule cells. Neuroscience Letters, 227, 177-180.
24. Cohen-Mansfield, J. and Werner, P. (1997). Management of verbally disruptive behaviors in nursing home residents. Journals of Gerontology Series A-Biological Sciences and Medical Sciences. 52, 369-377.
25. Cohen-Mansfield, J. et al. (1999). Withdrawal of haloperidol, thioridazine, and lorazepam in the nursing home: a controlled, double-blind study. Archives of International Medicine, 159, 1733-1740.
26. Committee of Safety of Medicines (CSM). Thioridazine: restricted indications and new warnings on cardiotoxicity. http:/medicines.mhra.gov.uk/ ourwork/monitorsafequalmed/safetymessages/urgent.htm#2000. Date final P. F. Date of access: December 11th 2000.
27. Committee of Safety of Medicines (CSM) (2004). Atypical antipsychotic drugs and stroke. http:/medicines.mhra.gov.uk/ourwork/monitorsafequalmed/ messages/risperidone-clinicaltrialdata final.pdf. Date of Access: May 13, 2004.
28. Court, J. A. et al. (2000). Nicotine-binding in human striatum: elevation in schizophrenia and reductions in dementia with Lewy bodies, Parkinson's disease and Alzheimer's disease; and in relation to neuroleptic medication. Neuroscience. 98, 79-87.
29. Davidson, M. et al. (2000). A long-term, multicentre, open-label study of risperidone in elderly patients with psychosis. International Journal of Geriatric Psychiatry, 15, 506-514.
30. De Deyn, P. P. et al. (1999). A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology, 53, 946-955.
31. De Deyn, P. P. et al. (2004). Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease. International Journal of Geriatric Psychiatry, 19, 115-126.
32. De Deyn, P. P. and Katz, I. R. (2000). Control of aggression and agitation in patients with dementia: efficacy and safety of risperidone. International Journal of Geriatric Psychiatry, 15, s14-s22.
33. Department of Health website, CEM/CMO/2000/181/atypical antipsychotic drugs and stroke, 9th march 2004.
34. Doody, R. S. et al. (2001). Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards sub-committee of the American Academy of Neurology, Neurology, 56, 1154-1166.
35. Edell, W. S. and Tunis, S. I. (2001). Antipsychotic treatment of behavioral and psychological symptoms of dementia in geropsychiatric inpatients. American Journal of Geriatric Psychiatry, 9, 289-297.
36. Finkel, S. (2004). Risperidone questioned as dementia first-line treatment. Geriatrics, 59, 11-12.
37. Finkel, S., Kozma, C., Long, S. and Engelhart, L. (2004). Risperidone treatment in elderly dementia patients. Relative risk of cardiovascular adverse life-events versus other antipsychotics. Poster presented at American Psychiatric Association Annual Meeting. 5-12 May, New York.
38. Finkel, S. I., Costa e Silva, J., Cohen, G., Miller, S., and Sartorius, N. (1996). Behavioral and psychological signs and symptoms of dementia: a consensus statement on current knowledge and implications for research and treatment. International Psychogeriatrics 8 (Suppl. 3), 497-500.
39. Foli, S., and Shah, A. (2000). Measurement of behaviour disturbance, non-cognitive symptoms and quality of life. In J. O'Brien, D. Ames and A. Burns (Eds.) Dementia (2nd ed.). (pp. 87-100). London: Edward Arnold.
40. Folstein, M. F., Folstein, S. E. and McHugh, P. R. (1975). "Mini-mental State". A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research, 12, 189-198.
41. Frenchman, I. B. (2000). Risperidone, haloperidol and olanzapine for the treatment of behaviour disturbances in nursing home patients: a retrospective analysis. Current Therapeutics, 61, 742-750.
42. Goldberg, R. J. and Goldberg, J (1997). Risperidone for dementia-related disturbed behaviour in nursing home residents: a clinical experience. International Psychogeriatrics, 9, 65-68.
43. Greenspan, A. J., Eerdekens, M. and Mahmoud, R. (2004). Is there an increased rate of cerebrovascular adverse events among patients with dementia? Presented at Annual Meeting of American Psychiatric Nurses Association (APNA). 13-16 October, Phoenix, Arizona.
44. Herrmann, N. (2004) Atypical antipsychotics and risk of cerebrovascular accidents. American Journal of Psychiatry, 161, 1113-1115.
45. Imamura, T. et al. (1999). Clinical diagnosis of dementia with Lewy bodies in a Japanese dementia registry. Dementia and Geriatric Cognitive Disorders, 10, 210-216.
46. Jeste, D. V., Lacro, J. P., Bailey, A., Rockwell, E. and Harris, M. J. (1999). Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients. Journal of the American Geriatrics Society, 47, 716-719.
47. Kallin, K., Jensen, J., Olsson, L. L., Nyberg, L. and Gustafson, Y. (2004). Why the elderly fall in residential care facilities, and suggested remedies. Journal of Family Practice, 53, 41-52
48. Katz, I. R., Jeste, D., Mintzer, J. E., Clyde, C., Napolitano, J. and Brecher, M. (1999). Comparison of risperidone and placebo for psychosis and behaviour disturbances associated with dementia: a randomized, double blind trial. Journal of Clinical Psychiatry, 60, 107-115.
49. Lonergan, E. (2003). Haloperidol for agitation in dementia. Cochrane Database. Systems Review.
50. Madhusoodanan, S., Brenner, R., Araujo, L. and Abaza, A. (1995). Efficacy of risperidone treatment for psychoses associated with schizophrenia, schizoaffective disorder, bipolar disorder, or senile dementia in 11 geriatric patients: a case-series. Journal of Clinical Psychiatry, 56, 514-518.
51. Madhusoodanan, S. et al. (2000). Efficacy and tolerability of olanzapine in elderly patients with psychotic disorders: a prospective study. Annals of Clinical Psychiatry, 12, 11-18.
52. Martin, H., Slyk, M. P., Deymann, S. D. and Cornacchione, M. J. (2003). Safety profile assessment of risperidone and olanzapine in long-term care patients with dementia. Journal of American Medical Directors Association, 4, 183-188.
53. Max, W., Webber, P. A. and Fox, P. J. (1995). Alzheimer's disease. The unpaid burden of caring. Journal of Ageing and Mental Health, 7, 179-199.
54. McKeith, I. et al. (1992). Neuroleptic sensitivity in patients with senile dementia of Lewy body type. British Medical Journal, 305, 673-678.
55. McKeith, I. G. et al. (2000). Prospective validation of consensus criteria for the diagnosis of dementia with Lewy bodies. Neurology, 54, 1050-1058.
56. McShane, R. et al. (1997). Do neuroleptic drugs hasten cognitive decline in dementia? Prospective study with necropsy follow-up. British Medical Journal, 314, 266-270.
57. Meehan, K. M. et al. (2000). Comparison of rapidly acting intramuscular olanzapine, lorazepam and placebo; a double-blind, randomised study in acutely agitated patients with dementia. Neuropsychopharmacology, 26, 494-504.
58. Negron, A. E. and Reichman, W. E. (2000). Risperidone in the treatment of patients with Alzheimer's disease with negative symptoms. International Psychogeriatrics, 12, 527-536.
59. Perry, E. K., Kilford, L., Lees, A. J., Burn, D. J. and Perry, R. H. (2003). Increased Alzheimer pathology in Parkinson's disease related to antimuscarinic drugs. Annals of Neurology, 54, 235-238.
60. Piggott, M. A. et al. (1998). Nigrostriatal dopaminergic activities in dementia with Lewy bodies in relation to neuroleptic sensitivity: comparisons with Parkinson's disease. Biological Psychiatry, 44, 765-774.
61. Rahkonen, T. et al. (2003). Dementia with Lewy bodies according to the consensus criteria in a general population aged 75 years or older. Journal of Neurology, Neurosurgery and Psychiatry, 74, 720-724.
62. Reilly, J. G. et al. (2000). QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet, 355, 1048-1052.
63. Rovner, B. W., Steele, C. D., Shmuely, Y. and Folstein, M. F. (1996). A randomized trial of dementia care in nursing homes. Journal of the American Geriatrics Society, 44, 7-13.
64. Rowe, M. A. and Fehrenbach, N. (2004). Injuries sustained by community-dwelling individuals with dementia. Clinical Nursing Research, 13, 98-110.
65. Sadek, J. and Rockwood, K. (2003). Coma with accidental single dose of an atypical neuroleptic in a patient with Lewy Body dementia. American Journal of Geriatric Psychiatry, 11, 112-113.
66. Saxe, T. (2004). Risperidone questioned as dementia first-line treatment. Geriatrics, 59, 11.
67. Schneider, L. S., Pollock, V. E. and Lyness, S. A. (1990). A meta-analysis of controlled trials of neuroleptic treatment in dementia. Journal of the American Geriatrics Society. 38, 553-563.
68. Scuffham, P., Chaplin, S. and Legood, R. (2003). Incidence and costs of unintentional falls in older people in the United Kingdom. Journal of Epidemiology and Community Health, 57, 740-744.
69. Shah, A. K. (1999). Aggressive behaviour in the elderly. International Journal of Psychiatry in Clinical Practice, 3, 85-103.
70. Smith, D. and Beier, M. (2004). Association between risperidone treatment and cerebrovascular adverse events: examining the evidence and postulating hypotheses for an underlying mechanism. Journal of the American Medical Directors Association, 5 (2), 129-132.
71. Street, J. S. et al. (2000). Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. Archives of General Psychiatry, 57, 968-976.
72. Suh, G. H. and Shah, A. (2001). A review of epidemiological transition in dementia: cross-national comparisons of the indices related to Alzheimer's disease and vascular dementia. Acta Psychiatrica Scandinavica, 104, 4-10.
73. Suh, G. H. and Shah, A. (2005). Effect of antipsychotics on mortality in the elderly with dementia: a 1-year prospective study in a nursing home. International Psychogeriatrics. (in press.)
74. Suh, G. H. et al. (2004). A randomised, double blind, crossover comparison of risperidone and haloperidol in Korean dementia patients with behaviour disturbance. American Journal of Geriatric Psychiatry, 12, 509-516.
75. Tariot, P. N., Profenno, L. A. and Ismail, M. S. (2004). Efficacy of atypical antipsychotics in elderly patients with dementia. Journal of Clinical Psychiatry, 65, (Suppl. 11), 11-15.
76. Teri, L. et al. (2000). Alzheimer's Disease Cooperative Study. Treatment of agitation in AD: a randomized, placebo-controlled clinical trial. Neurology, 55, 1271-1278.
77. Tune, L. E., Steele, C. and Cooper, T. (1991). Neuroleptic drugs in the management of behavioral symptoms of Alzheimer's Disease. Psychiatric Clinics of North America, 14, 353-373.
78. van Doorn, C. et al. (2003). Epidemiology of Dementia in Nursing Homes Research Group. Dementia as a risk factor for falls and fall injuries among nursing home residents. Journal of the American Geriatrics Society, 51, 1213-1218.
79. Verma, S., Orengo, C. A., Kunik, M. E., Hale, D. and Molinari, V. A. (2001). Tolerability and effectiveness of atypical antipsychotics in male geriatric inpatients. International Journal of Geriatric Psychiatry, 16, 223-227.
80. Wancata, J. (2004a). Efficacy of risperidone for treating patients with behavioral and psychological symptoms of dementia. International Psychogeriatrics, 16, 107-115.
81. Wancata, J. (2004b). Cerebrovascular events after treatment of dementia patients with risperidone. International Psychogeriatrics, 16, 493-495.
82. Wooltorton, E. (2002). Risperidone (risperidal): increased rate of cerebrovascular events in dementia trials. Canadian Medical Association Journal, 167, 1269-1270.
83. Zarate, C. A. et al. (1997). Risperidone in the elderly: a pharmacoepidemiologic study. Journal of Clinical Psychiatry, 58, 311-317.